Plain-English translation of NCT06271707 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a procedure called a stellate ganglion block — an ultrasound-guided injection that numbs a specific nerve in the chest — can help prevent atrial fibrillation (irregular heartbeat) after major lung surgery. Researchers will compare patients who receive this nerve block with bupivacaine, a numbing medication, to patients who receive a placebo injection, to see which group has fewer heart rhythm problems after surgery.
Irregular heartbeat is a common and serious complication after lung surgery, and current standard care doesn't always prevent it. This trial is exploring whether this nerve block technique might reduce that risk and improve outcomes for patients having these operations.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive your planned lung surgery. During the operation, you will be randomly assigned to receive either a nerve block injection with numbing medication or a saline placebo injection — neither you nor your surgical team will know which one you're getting. After surgery, researchers will monitor you for irregular heartbeat and other complications to compare the two groups.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Sponsor
University of Minnesota
Enrollment target
~48 participants
Started
May 2025
Primary completion
April 2027
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Candace Nelson
University of Minnesota
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.